PCVX
Vaxcyte, Inc.
Key Financials
Operating Income
$-923675000
↓ 62.2%
Net Income
$-766628000
↓ 65.2%
Total Assets
$3.0B
↓ 14.5%
Total Liabilities
$317.2M
↑ 54.4%
Shareholders' Equity
$2.7B
↓ 18.8%
EPS (Diluted)
$-5.63
↓ 48.2%
Cash & Equivalents
$174.0M
↓ 55.2%
Dividends/Share
$0.00
NaN%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 10/2/2026 | View on SEC |
| 144 | 10/1/2026 | View on SEC |
| 4 | 9/9/2026 | View on SEC |
| 4 | 9/9/2026 | View on SEC |
| 4 | 9/9/2026 | View on SEC |
| 4 | 9/9/2026 | View on SEC |
| 4 | 9/9/2026 | View on SEC |
| 4 | 9/9/2026 | View on SEC |
| 3 | 9/9/2026 | View on SEC |
| 144 | 9/9/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | PCVX |
| Company Name | Vaxcyte, Inc. |
| CIK | 1649094 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 650-837-0111 |